Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects
AUTOR(ES)
Sposito, A.C., Mansur, A.P., Maranhão, R.C., Rodrigues-Sobrinho, C.R.M., Coelho, O.R., Ramires, J.A.F.
FONTE
Brazilian Journal of Medical and Biological Research
DATA DE PUBLICAÇÃO
2001-02
RESUMO
Etofibrate is a hybrid drug which combines niacin with clofibrate. After contact with plasma hydrolases, both constituents are gradually released in a controlled-release manner. In this study, we compared the effects of etofibrate and controlled-release niacin on lipid profile and plasma lipoprotein (a) (Lp(a)) levels of patients with triglyceride levels of 200 to 400 mg/dl, total cholesterol above 240 mg/dl and Lp(a) above 40 mg/dl. These patients were randomly assigned to a double-blind 16-week treatment period with etofibrate (500 mg twice daily, N = 14) or niacin (500 mg twice daily, N = 11). In both treatment groups total cholesterol, VLDL cholesterol and triglycerides were equally reduced and high-density lipoprotein cholesterol was increased. Etofibrate, but not niacin, reduced Lp(a) by 26% and low-density lipoprotein (LDL) cholesterol by 23%. The hybrid compound etofibrate produced a more effective reduction in plasma LDL cholesterol and Lp(a) levels than controlled-release niacin in type IIb dyslipidemic subjects.
Documentos Relacionados
- Controlled-release Fertilizer in the Production and Quality of Acacia mangium Seedlings
- Controlled-Release Fertilizer on Growth of Melanoxylon brauna Schott Seedlings
- Controlled-Release Carbamazepine Granules and Tablets Comprising Lipophilic and Hydrophilic Matrix Components
- Development and Evaluation of oral multiple-unit and single-unit hydrophilic controlled-release systems
- Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine.